Why the study?
Reports emerged of myocarditis and pericarditis predominantly in young males after the second dose of mRNA COVID-19 vaccines, prompting a review of benefits and risks.
Do the benefits of mRNA COVID-19 vaccines outweigh the risks of myocarditis in persons aged ≥12 years?
Do the benefits of mRNA COVID-19 vaccines outweigh the risks of myocarditis in persons aged ≥12 years?
The ACIP recommends continued use of mRNA COVID-19 vaccines in all eligible populations, concluding that the benefits of vaccination clearly outweigh the rare risk of myocarditis.
No takes yet. Share an insight, caveat, or question.
Supports continued mRNA COVID-19 vaccination for all persons aged ≥12 years; reinforces ACIP guidance with updated risk-benefit data.
Gargano et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: